TY  - JOUR
T1  - THe case for dual renin-angiotensin system inhibition
AU  - Hirsch S
Y1  - 2009/11/09
N1  - 10.1001/archinternmed.2009.406
JO  - Archives of Internal Medicine
SP  - 1931
EP  - 1931
VL  - 169
IS  - 20
N2  - 
Ku et al1 cite the findings of the Renal Outcomes With Telmisartan, Ramipril, or Both, in People at High Vascular Risk (ONTARGET) trial2 in arguing against dual renin-angiotensin system (RAS) inhibition in chronic kidney disease. However, the ONTARGET trial evaluated patients with less than 1 g of proteinuria, many of whom were normotensive. This was not a study of patients for whom nephrologists typically consider dual RAS inhibition; ONTARGET does not address, much less rebut, the efficacy of dual RAS inhibition that has been demonstrated in the hypertensive, proteinuric cohort.3

SN  - 0003-9926
M3  - doi: 10.1001/archinternmed.2009.406
UR  - http://dx.doi.org/10.1001/archinternmed.2009.406
ER  -